Cadisegliatin (TTP399) is a novel, oral small molecule, liver selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment to insulin for type 1 diabetes ...
I maintain a buy rating on VTV due to its strong momentum, low cost, and solid technical trend despite concerns about valuation. VTV's portfolio is well-diversified, with significant exposure to large ...
vTv Therapeutics Inc (VTVT) Stock Split History Explore the full vTv Therapeutics Inc (VTVT) stock split history. Explore the vTv Therapeutics Inc stock split dates, split ratios, and view how many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback